SOJE Operating Expenses

Southern Company (The) Series 2020C 4.20% Junior Subordinated Notes due October 15, 2060 · Operating Expenses

SOJE logo

SOJE Operating Expenses

Latest reported$1.80B
SOJE Quarterly Operating Expenses ($1.92B → $1.80B)
High-resolution chart · PNG

SOJE operating expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Southern Company (The) Series 2020C 4.20% Junior Subordinated Notes due October 15, 2060 Operating Expenses — Quarterly (USD)
Period endingOperating Expenses (USD)
1,801,000,000
1,884,000,000
402,000,000
1,710,000,000
1,726,000,000
1,731,000,000
1,603,000,000
1,585,000,000
1,545,000,000
1,541,000,000
1,281,000,000
1,644,000,000
1,452,000,000
1,505,000,000
1,721,000,000
1,204,000,000
1,314,000,000
1,241,000,000
2,143,000,000
1,347,000,000
1,653,000,000
1,220,000,000
1,351,000,000
1,193,000,000
1,320,000,000
1,148,000,000
1,053,000,000
1,167,000,000
1,046,000,000
-1,417,000,000
1,149,000,000
790,000,000
2,195,000,000
1,168,000,000
1,290,000,000
1,104,000,000
4,074,000,000
1,154,000,000
1,195,000,000
1,092,000,000
905,000,000
850,000,000
938,000,000
942,000,000
768,000,000
748,000,000
730,000,000
1,190,000,000
750,000,000
1,124,000,000
743,000,000
873,000,000
1,158,000,000
1,241,000,000
-1,327,000,000
686,000,000
654,000,000
666,000,000
2,343,000,000
3,305,000,000
2,703,000,000
2,436,000,000
2,217,404,000
3,141,000,000
2,451,000,000
2,385,000,000
2,080,602,000
1,365,888,000
2,302,838,000
2,152,396,000
2,064,672,000
2,895,412,000
2,395,853,000
2,138,063,000
1,927,776,000
2,811,861,000
2,214,286,000
2,028,077,000
1,921,245,000
2,684,441,000
2,145,010,000
1,910,304,000
1,876,918,000
2,602,331,000
2,002,728,000
1,824,193,000
-529,177,000
2,270,541,000
1,920,829,000
1,773,785,000
-494,980,000
2,226,006,000
1,971,222,000
1,723,042,000
-465,655,000
2,219,293,000
1,820,584,000
1,571,778,000
-325,193,000
2,075,615,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.